Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-05-09 00:00:00 ET · period of report 2023-05-05 · accession 0001209191-23-028243 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-05-09 | 2023-05-05+ | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $350.00 | -3,272 | 34.9K | -9% | -$1.15M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-08 | S | D | 2,850 | $350.00 | 32,038 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-05 | S | D | 422 | $350.03 | 34,888 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $350.03 (range $350.00 to $350.40). (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |